Effect of Omega 3 Fatty Acids on Vascular Function
Effect of Omega 3 Fatty Acid Supplementation on Endothelial Function, Endogenous Fibrinolysis and Platelet Activation in Patients With a Previous Myocardial Infarction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH16 4SB
- Centre for Cardiovascular Sciences, University of Edinburgh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• Myocardial infarction at least 3 months previously.
Exclusion Criteria:
- Dietary fish allergy or intolerance
- Women of child bearing potential
- Malignant arrhythmias
- Renal or hepatic failure
- Severe or significant co-morbidity
- Previous history of blood dyscrasia
- Unable to tolerate the supine position
- Lack of informed consent
- Blood donation within last 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Omega 3 fatty acid supplementation
Omacor 2 grams daily
|
2 grams Omacor daily
|
|
Placebo Comparator: Olive Oil
Olive Oil capsule 2 grams daily
|
2 grams olive oil daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endogenous fibrinolysis (net release of plasma t-PA,IU mL-1)
Time Frame: Measured at 6 weeks after omega 3 fatty acids or placebo
|
Endogenous fibrinolysis was measured by drawing blood during intrabrachial substance P infusion and then plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit; Technoclone, Vienna, Austria) concentrations were determined by enzyme-linked immunosorbent assays.
Estimated net release of plasma t-PA was the product of the infused forearm plasma flow (based on the mean hematocrit and the infused forearm blood flow) and the concentration difference between the infused and noninfused arms.
|
Measured at 6 weeks after omega 3 fatty acids or placebo
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endothelial vasomotor function (forearm blood flow, mL l00 mL-1 min-1)
Time Frame: Measured at 6 weeks after omega 3 fatty acids or placebo
|
Forearm blood flow was measured during intrabrachial infusions of acetylcholine, substance P and sodium nitroprusside by venous occlusion plethysmography with mercury-in-silicone elastomer strain gauges.
|
Measured at 6 weeks after omega 3 fatty acids or placebo
|
|
Circulating platelet-monocyte aggregates (%).
Time Frame: Measured at 6 weeks after omega 3 fatty acids or placebo
|
Whole blood was immunolabelled with appropriate monoclonal antibodies for subsequent flow cytometric analysis of platelet-monocyte aggregation.
Platelet-monocyte aggregates were defined as the percentage of monocytes positive for CD42a.
|
Measured at 6 weeks after omega 3 fatty acids or placebo
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: David E Newby, University of Edinburgh
- Principal Investigator: Jehangir N Din, University of Edinburgh
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LREC/2003/8/13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.